Publications by authors named "V Dipasquale"
Background And Aims: Patients with very early-onset inflammatory bowel disease (VEO-IBD), with an age of onset < 6 years, can present with severe manifestations and may require biologic therapy. Infliximab and adalimumab are approved for induction and maintenance in pediatric IBD patients but are licensed only above the age of 6 years. Effectiveness and safety data on adalimumab in this patient population are lacking.
View Article and Find Full Text PDFArticle Synopsis
- Infliximab is a special medicine used to treat diseases like rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), and GP1111 (Zessly®) is a new version of it approved in Europe.
- A review showed that GP1111 has similar effectiveness and safety when compared to the original infliximab, even after patients switched to it from other similar medicines.
- Real-world evidence suggests that using GP1111 is safe and cost-effective for patients with RA and IBD, supporting its continued use.
Chronic kidney disease (CKD) encompasses diverse conditions such as congenital anomalies, glomerulonephritis, and hereditary nephropathies, necessitating individualized nutritional interventions. Early detection is pivotal due to the heightened risk of adverse outcomes, including compromised growth and increased healthcare costs. The nutritional assessment in pediatric CKD employs a comprehensive, multidisciplinary approach, considering disease-specific factors, growth metrics, and dietary habits.
View Article and Find Full Text PDFThis study reports the complication and disease recurrence rates for ileocecal resection for pediatric and adult Crohn's disease (CD) and identifies perioperative risk factors for these adverse outcomes in the two groups. Patients who underwent ileocecal resection for CD in a tertiary hospital in Italy (2010-2021) were included. Risk factors for postoperative complications and clinical and surgical disease recurrences were investigated with multivariate models.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effectiveness and safety of adalimumab biosimilar (ADL-BioS) for treating pediatric patients with inflammatory bowel disease (IBD), as data on this topic is limited.
- It involved 41 pediatric IBD patients treated with ADL-BioS from 2019 to 2021, measuring outcomes such as clinical remission at 14 and 52 weeks, treatment persistence, and adverse events.
- Results showed that approximately 71% achieved remission, treatment persistence was high at 85.4%, and only a small percentage experienced adverse events, suggesting that ADL-BioS is an effective and safe option for pediatric IBD patients.